Evaluation of Fosmidomycin and Piperaquine in the Treatment of Acute Falciparum Malaria

A Phase IIa Proof of Concept Study to Explore the Efficacy, Tolerability and Safety of Fosmidomycin Sodium When Administered With Piperaquine Tetraphosphate to Adults and Older Children With Acute Uncomplicated Plasmodium Falciparum Malaria

NCT02198807•Jomaa Pharma GmbH

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Oral Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria

Interventions

Fosmidomycin-Piperaquine

Key Dates

Start Date

March 1, 2014

Primary Completion Date

July 1, 2014

Completion Date

December 1, 2015

Last Updated

June 15, 2015

Sponsors

Lead Sponsor

Jomaa Pharma GmbH

Collaborators

Centre de Recherche Médicale de Lambaréné

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 15, 2015Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions